BIIB241206P200000
- 19.58
- 0.000.00%
Biogen Newsroom
Eisai And Biogen : Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment
The annual "big reshuffling" of the Nasdaq 100 is about to begin! Who is expected to join, and who will be eliminated?
This year's potential high-flying stocks like palantir, MSTR and more are expected to be included.
Express News | "Leqembi®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Electronic Arts, Lyft and 7 More Stocks That Can Benefit From Trump's R&D Policy
Express News | Biogen Shares Down 2% at $160.80 in Volume Spike
Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript
Express News | Biogen Exec Says Co Expects "a Linear Trend" of About $10 Million in U.S. Sales per Quarter for Leqembi in the Near-Term - Conf Call
Palantir, MicroStrategy Lead List of Stocks That Could Join Nasdaq 100
10 Health Care Stocks With Whale Alerts In Today's Session
Express News | Japan Health Ministry Panel Endorses Biogen's ALS Drug Tofersen, Kyodo Says
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024?
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
"LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials Driving The Negative Sentiment?
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink?
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC